These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 26810718)

  • 41. Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders.
    Amaral JM; Talim N; Kleinpaul R; Lana-Peixoto MA;
    Mult Scler Relat Disord; 2020 Jun; 41():102045. PubMed ID: 32179485
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic options in neuromyelitis optica spectrum disorders.
    Kitley J; Palace J
    Expert Rev Neurother; 2016; 16(3):319-29. PubMed ID: 26840802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive value of MRI parameters in severity and recovery of first-episode myelitis in aquaporin-4 antibody disease.
    Murchison A; Kitley J; Leite MI; Küker W; Palace J
    J Neurol Sci; 2015 Aug; 355(1-2):49-53. PubMed ID: 26026944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature.
    Aungsumart S; Apiwattanakul M
    Mult Scler Relat Disord; 2017 Apr; 13():93-97. PubMed ID: 28427710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate.
    Ramanathan RS; Malhotra K; Scott T
    BMC Neurol; 2014 Mar; 14():51. PubMed ID: 24628894
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients.
    Zecca C; Disanto G; Sacco R; Riccitelli GC; Gobbi C
    BMC Neurol; 2019 Jul; 19(1):159. PubMed ID: 31299922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder.
    Chen B; Wu Q; Ke G; Bu B
    Sci Rep; 2017 Apr; 7(1):831. PubMed ID: 28400553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
    Martinelli Boneschi F; Rovaris M; Johnson KP; Miller A; Wolinsky JS; Ladkani D; Shifroni G; Comi G; Filippi M
    Mult Scler; 2003 Aug; 9(4):349-55. PubMed ID: 12926839
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder.
    Zhou Y; Zhong X; Shu Y; Cui C; Wang J; Wang Y; Li X; Chen Z; Peng L; Kermode A; Qiu W
    Mult Scler Relat Disord; 2019 Feb; 28():213-220. PubMed ID: 30623860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China.
    Huang Q; Wang J; Zhou Y; Yang H; Wang Z; Yan Z; Long Y; Yin J; Feng H; Li C; Lu Z; Hu X; Qiu W
    Front Immunol; 2018; 9():2066. PubMed ID: 30258442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glatiramer acetate could be a hypothetical therapeutic agent for neuromyelitis optica.
    Wang KC; Lee CL; Chen SY; Lin KH; Tsai CP
    Med Hypotheses; 2011 Jun; 76(6):820-2. PubMed ID: 21398045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuromyelitis optica spectrum disorders.
    Huda S; Whittam D; Bhojak M; Chamberlain J; Noonan C; Jacob A
    Clin Med (Lond); 2019 Mar; 19(2):169-176. PubMed ID: 30872305
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder.
    Park JH; Hwang J; Min JH; Kim BJ; Kang ES; Lee KH
    J Neurol Sci; 2015 Jan; 348(1-2):132-5. PubMed ID: 25500159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases.
    Katsumata Y; Kawachi I; Kawaguchi Y; Gono T; Ichida H; Hara M; Yamanaka H
    Mod Rheumatol; 2012 Sep; 22(5):676-84. PubMed ID: 22183613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
    Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I
    BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glatiramer acetate treatment in Devic's neuromyelitis optica.
    Bergamaschi R
    Brain; 2003 Jun; 126(Pt 6):1E; author reply 1E-a. PubMed ID: 12764069
    [No Abstract]   [Full Text] [Related]  

  • 60. Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?
    de Seze J; Collongues N
    Expert Rev Clin Immunol; 2013 Oct; 9(10):979-86. PubMed ID: 24128159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.